... aspx?SID = 313〈 = ar. 90 Abd al-Latif al-Baghdadi, Mudhakirat ‘Abd al-Latif al-Baghdadi [The Memoirs of Abd al-Latif al-Baghdadi] (Cairo: Al-Maktab al-Misri al-Hadith, 1977), ... 109 Heikal, Milaffat al-Suways, p. 347.110 Al-Baghdadi, Mudhakirat ‘Abd al-Latif al-Baghdadi, p. 202.111 On Israeli influence, see Muhammad ... 15 November 1955, p. 771.115 Cited in al-Baghdadi, Mudhakirat ‘Abd al-Latif al-Baghdadi, p. 205.116 Al-Baghdadi, Mudhakirat ‘Abd al-Latif al-Baghdadi, p. 213.117 ENA: FM-1248/10, Egyptian ...
Tópico(s): Historical Geopolitical and Social Dynamics
2014 - Routledge | British Journal of Middle Eastern Studies
... to Napoleoni, ISIS and its leader Abu Bakr al Baghdadi are viewed by many Sunnis in Iraq as ... Zarqawi's jihad. (14) ISIS's spiritual leader, al Baghdadi, presents himself to members of the Caliphate as ... of his official appearance after being elected Caliph, al Baghdadi spoke inside the Grand Mosque of Mosul dressed ... imam. (16) In his speech to his followers, al Baghdadi shows himself as a wise and pragmatic religious ... long as I obey God in you. (17) Al Baghdadi also portrays ISIS to its followers (and the ...
Tópico(s): Terrorism, Counterterrorism, and Political Violence
2015 - United States Army War College | The US Army War College Quarterly Parameters
... were raised by the philosopher ‘Abd al-Laṭīf al-Baghdādī (d. ca. 1231 CE) against al-Ḥasan ibn ... contrast the philosophical propositions that were advanced by al-Baghdādī in his tract: Fī al-Radd ‘alā Ibn ... Discourse on place ). In examining the particulars of al-Baghdādī’s fragile defence of Aristotle’s definition of ...
Tópico(s): Historical, Religious, and Philosophical Studies
2007 - Cambridge University Press | Arabic Sciences and Philosophy
Mohamed Deyab, Seham E. Abu Ahmed, Fatma Ward,
... characteristics of surface water at the seven sites (Al-Baghdadi, Shatta, El-Deiba, Abo El-Ross, El Nafft, ... varied in relation with water quality as follows: Al-Baghdadi > El Nafft > Shatt Greba > Shatta > El-Deiba > Towall ... the dominant class at all sites except at Al-Baghdadi and Towall Ibrahim where Bacillariophyta and Pyrrophyta were ...
Tópico(s): Marine and coastal ecosystems
2019 - Springer Science+Business Media | International Journal of Environmental Science and Technology
... how much words matter to Daesh.Abu Bakr al-Baghdadi al-Quraishi, Leader of DaeshVerily the chiefest among ... MohammadThe Daesh leader uses the name Abu Bakr al-Baghdadi al-Quraishi for its religious significance. While not ... or caliph. The Daesh leader's middle name, al-Baghdadi, refers to someone from Baghdad, and his last ...
Tópico(s): Terrorism, Counterterrorism, and Political Violence
2016 - The MIT Press | Military review
Christopher A. Miller, Jason Walker, Travis L. Jensen, William F. Hooper, Robert S. Fulton, Jeffrey S. Painter, Mikkael A. Sekeres, Timothy J. Ley, David H. Spencer, Johannes B. Goll, Matthew J. Walter,
... J.W. Waclawiw M.A. Liu J.J. Al Baghdadi T. Walter M.J. Bejar R. Gorak E. ... J.W. Waclawiw M.A. Liu J.J. Al Baghdadi T. Walter M.J. Bejar R. Gorak E. ...
Tópico(s): Cancer Genomics and Diagnostics
2022 - Elsevier BV | Journal of Molecular Diagnostics
... prometido lealtad al lider del EI, Abu Bakr al Baghdadi, estan radicalizando a los musulmanes y llevando a ... have pledged allegiance to IS leader Abu Bakr al Baghdadi are radicalising Muslims and conducting attacks. Harnessing both ...
Tópico(s): Law, Ethics, and AI Impact
2019 - UNISCI | UNISCI Journal
... research is to compare groundwater recharge in Khan Al-Baghdadi area which located to northwest of Anbar governorate ...
Tópico(s): Groundwater and Watershed Analysis
2018 - College of Science for Women, University of Baghdad | Iraqi Journal of Science
Haider Al-Baghdadi, Çiğdem Koca Al-Baghdadi, Abdikarim Abdi, Onur Gültekin, Arijana Meštrović, Rümeysa Demirdamar, Barçın Özçem, Bilgen Başgut,
Tópico(s): Cardiac, Anesthesia and Surgical Outcomes
2017 - Springer Science+Business Media | International Journal of Clinical Pharmacy
... Pakistan (aka Al Qaeda Central) repudiated Abu Bakr al-Baghdadi, the leader of Al Qaeda in Iraq. Ayman al-Zawahiri declared that al-Baghdadi and his newly formed Islamic State in Iraq ...
Tópico(s): Energetic Materials and Combustion
2015 - Taylor & Francis | Studies in Conflict and Terrorism
... a to the group’s leader, Abu Bakr al-Baghdadi, and his project is a contested issue among ... their calls for allegiance to “caliph” Abu Bakr al-Baghdadi and how radical Islamist critics of IS have ...
Tópico(s): Education and Islamic Studies
2015 - University of Massachusetts Lowell | Perspectives on terrorism
... pp. 50, 70. Audio statement by Abu Bakr al-Baghdadi, 10 April 2013. Thomas Joscelyn, 'Al Nusrah Front ... Point. Ibid. Ibid. Audio statement by Abu Bakr al-Baghdadi, April 2013. Audio statement by Abu Muhammad al- ...
Tópico(s): Terrorism, Counterterrorism, and Political Violence
2013 - Taylor & Francis | Survival
N. Peter Joosse, Peter E. Pormann,
'Abd al-Laṭīf al-Baghdādī's (d. 1231) work Book of the Two Pieces ofAdvice (Kitāb al Nasīḥatayn) challenges the idea that Islamic medicine ...
Tópico(s): History of Medicine Studies
2010 - Johns Hopkins University Press | Bulletin of the history of medicine
... four main sects noted in the heresiographies of al-Baghdadi Citation(2002), al-Farq bayna al-Firaq; al- ... l-Nihal: book of religious and philosophical sects; al-Baghdadi Citation(1935), Al-Farq bayna al-Firaq; and ...
Tópico(s): Historical and Linguistic Studies
2010 - Taylor & Francis | The Journal of North African Studies
Rasha Al-Qaisi, Abdulkhaleq A. Alhadithi, Aboosh H. Al-Hadidy,
... within Abu-Jir fault zone has distinguished as “Al-Baghdadi sub-basin” after Al-Baghdadi city. It has NW–SE trending align the western bank of the Euphrates. Al-Baghdadi sub-basin is a local basin, which forms ... are also variations in lithofacies between outcrops within Al-Baghdadi sub-basin as revealed from lateral missing or ...
Tópico(s): earthquake and tectonic studies
2022 - IOP Publishing | IOP Conference Series Earth and Environmental Science
Ali Badeen Mohammed Al-Rikaby, Tengku Sepora Tengku Mahadi,
... significance of the discursive strategies in Abu Bakr al-Baghdadi’s and Ayman al-Zawahiri’s jihadi rhetoric ... calls for jihad by al-Zawahiri (2006) and al-Baghdadi (2015) to exemplify their jihadist ideology giving much ...
Tópico(s): Rhetoric and Communication Studies
2018 - John Benjamins Publishing Company | Journal of Language and Politics
S. Hussien, Firas Mudhafar Abdulhussein,
... study of the surface and groundwater in Khan AL-Baghdadi area, western Iraq, included the interpretation of physical, ...
Tópico(s): Transboundary Water Resource Management
2021 - College of Science for Women, University of Baghdad | Iraqi Journal of Science
Sandip Pravin Patel, Megan Othus, Young Kwang Chae, Francis J. Giles, Donna E. Hansel, Preet Paul Singh, Annette Fontaine, Manisha H. Shah, Anup Kasi, Tareq Al Baghdadi, Marc Matrana, Zoran Gatalica, W. Michael Korn, Jourdain Hayward, Christine MMcLeod, Helen X. Chen, Elad Sharon, Edward Mayerson, Christopher W. Ryan, Melissa Plets, Charles D. Blanke, Razelle Kurzrock,
... Singh, Annette Fontaine, Manisha Shah, Anup Kasi, Tareq Al Baghdadi, Marc Matrana, Zoran Gatalica, W. Michael Korn, Jourdain ...
Tópico(s): Neuroblastoma Research and Treatments
2019 - American Association for Cancer Research | Cancer Research
At the end of June 2014, Abu Baqr al-Baghdadi, the leader of what was to become Da' ... the obvious political rhetoric that the announcement involved, al-Baghdadi's aspirations raised interesting questions of historical and ...
Tópico(s): Middle East and Rwanda Conflicts
2017 - Taylor & Francis | Geopolitics
Jordi Rodón, Estelamari Rodriguez, Michael L. Maitland, Frank Tsai, Mark A. Socinski, Jordan Berlin, Jacob Thomas, Tareq Al Baghdadi, I.‐M. Wang, Cunlan Guo, Mohammad‐Taghi Golmakani, Lorraine N. Clark, Mihaela Gazdoiu, M. Li, A. W. Tolcher,
•This is a first-in-human dose-escalation/expansion study of PF-06939999, a selective small-molecule inhibitor of PRMT5.•Patients with selected solid tumors were treated with PF-06939999 0.5-12 mg daily (q.d. or b.i.d.).•PF-06939999 had a tolerable safety profile. Most common ≥G3 treatment-related AEs: hematological toxicities. RP2D: 6 mg q.d.•Response was seen in a subset of patients with metastatic NSCLC and HNSCC, suggesting PRMT5 is a cancer therapeutic target.•No predictive biomarker was identified. ...
Tópico(s): Epigenetics and DNA Methylation
2024 - Elsevier BV | ESMO Open
Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, Guilherme Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily Hinchcliff, Shashikant Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian,
Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (stage III or IVA) or stage IVB or recurrent endometrial cancer in a 1:1 ratio to receive pembrolizumab or placebo along with combination therapy with paclitaxel plus carboplatin. The administration of pembrolizumab or placebo ...
Tópico(s): Genetic factors in colorectal cancer
2023 - Massachusetts Medical Society | New England Journal of Medicine
Herbert L. Duvivier, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer, Eugene Ahn, Tareq Al Baghdadi, Ajjai Alva, Stephanie A. Dublis, Timothy Lewis Cannon, Carmen Calfa, Rui Li, Deepti Behl, Vi K. Chiu, Philip J. Gold, Alissa Marr, Kathryn F. Mileham, Steven Powell, Jordi Rodón, Ramya Thota, Gina N. Grantham, Abigail Gregory, Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky,
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a pragmatic basket trial evaluating antitumor activity of approved targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from cohorts of patients with high tumor mutational burden (HTMB, defined as ≥9 mutations per megabase) with advanced colorectal cancer (CRC) and other advanced cancers treated with pembrolizumab are reported.Eligible patients were 18 years and older with measurable ...
Tópico(s): Genetic factors in colorectal cancer
2023 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
J. Joshua Smith, Arvind Dasari, Qian Shi, Julio García‐Aguilar, Hanna K. Sanoff, Thomas J. George, Theodore S. Hong, Greg Yothers, Philip Agop Philip, Garth D. Nelson, Tareq Al Baghdadi, Olatunji B. Alese, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Ardaman Shergill, Natally Horvat, Paul B. Romesser, William A. Hall,
TPS3640 Background: Recent data have demonstrated that in locally advanced rectal cancer (LARC), a total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of tumor response compared to neoadjuvant chemoradiation (CRT) alone. They further indicate that the optimal sequencing of TNT involves consolidation (rather than induction) chemotherapy to optimize complete response rates. Data, largely from retrospective studies, have also shown that patients (pts) with ...
Tópico(s): Clinical practice guidelines implementation
2023 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
William A. Hall, Jiahe Li, Y. Nancy You, Marc J. Gollub, Joseph R. Grajo, Mark Rosen, Greg dePrisco, Greg Yothers, Jennifer A. Dorth, Osama E. Rahma, Marcia M. Russell, Howard M. Gross, Samuel A. Jacobs, Bryan A. Faller, Sagila George, Tareq Al Baghdadi, Michael G. Haddock, Richard K. Valicenti, Theodore S. Hong, Thomas J. George,
Total neoadjuvant therapy (TNT) is a newly established standard treatment for rectal adenocarcinoma. Current methods to communicate magnitudes of regression during TNT are subjective and imprecise. Magnetic resonance tumor regression grade (MR-TRG) is an existing, but rarely used, regression grading system. Prospective validation of MR-TRG correlation with pathologic response in patients undergoing TNT is lacking. Utility of adding diffusion-weighted imaging to MR-TRG is also unknown.
Tópico(s): MRI in cancer diagnosis
2023 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Deborah Schrag, Qian Shi, Martin R. Weiser, Marc J. Gollub, Leonard B. Saltz, Benjamin Musher, Joel E. Goldberg, Tareq Al Baghdadi, Karyn A. Goodman, Robert R. McWilliams, Jeffrey M. Farma, Thomas J. George, Hagen F. Kennecke, Ardaman Shergill, Michael Montemurro, Garth D. Nelson, Brian Colgrove, Vallerie Gordon, Alan P. Venook, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Amylou C. Dueck, Ethan Basch, George J. Chang, Harvey J. Mamon,
Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) can be used in lieu of chemoradiotherapy is uncertain. Download a PDF of the Research Summary. We conducted a multicenter, unblinded, noninferiority, randomized trial of neoadjuvant FOLFOX (with chemoradiotherapy given only if the primary ...
Tópico(s): Colorectal Cancer Screening and Detection
2023 - Massachusetts Medical Society | New England Journal of Medicine
Aimen Zeiny, Maher A.R. Sadiq Al-Baghdadi, Ward F. Arear, M.S. Ismail,
Polymer electrolyte membrane (PEM) fuel cells are promising eco-friendly and sustainable power generation technology. Thermal management of these cells is one of the main challenges facing their commercialization. Alumina nanofluids, in addition to others, have been proposed to overcome excess heat generated within the PEM fuel cell stacks. However, most the previous studies investigated the hydrothermal performance of the nanofluids as a function of Reynolds number (Re). It is evident that all parameters ...
Tópico(s): Heat transfer and supercritical fluids
2022 - Elsevier BV | International Journal of Hydrogen Energy
Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Katherine Minichiello, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi, Susan J. Hines, Leah Everhart, Louise Highleyman, Vassiliki A. Papadimitrakopoulou, Joel W. Neal, Saiama N. Waqar, Jyoti D. Patel, Jhanelle E. Gray, David R. Gandara, Karen Kelly, Roy S. Herbst,
PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising results in multiple tumor types. METHODS In this randomized phase II Lung-MAP nonmatch substudy (S1800A), patients ineligible for a biomarker-matched substudy with NSCLC previously treated with ICI and platinum-based chemotherapy and progressive disease at least ...
Tópico(s): Lung Cancer Diagnosis and Treatment
2022 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross, Priya Rastogi, Karen Cui, Amal Arahmani, Gursel Aktan, Anne Armstrong, Mónica Arnedos, Judith Balmaña, Jonas Bergh, Judith M. Bliss, Suzette Delaloge, Susan M. Domchek, Andrea Eisen, F. Elsafy, L.E. Fein, Anitra Fielding, James M. Ford, Sue Friedman, Karen A. Gelmon, Luca Gianni, Michael Gnant, Simon J. Hollingsworth, Seock‐Ah Im, Agnes Jager, Oskar T. Johannsson, Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke, Mustafa Aydoğdu, Christoph Thomssen, Joachim Rom, Christine Mau, Peter A. Fasching, Uwe-Jochen Göhring, Thorsten Kühn, S Noeding, Sherko Kümmel, John Hackmann, Elmar Stickeler, Abhishek Joshi, Joanna Dewar, Michael Friedlander, Kelly‐Anne Phillips, Yoland Antill, Natasha Woodward, Ehtesham Abdi, Susan Tiley, Mathew George, David Boadle, Annabel Goodwin, André van der Westhuizen, George Kannourakis, N. Murray, Nicole McCarthy, Judith R. Kroep, Maaike de Boer, Joan B. Heijns, Agnes Jager, Franciscus Erdkamp, Sandra D. Bakker, Gabe S. Sonke, Amer Sami, John M. Mackey, Catherine Prady, Andrea Eisen, Christine Desbiens, Érica Patocskai, Cristiano Ferrario, Karen A. Gelmon, Louise Bordeleau, Haji Chalchal, Saroj Niraula, Ido Wolf, Elżbieta Senkus, François Duhoux, Randal D’hondt, Sylvie Luce, Daphné t’Kint de Roodenbeke, Konstantinos Papadimitriou, Marleen Borms, Claire Quaghebeur, William Jacot, Etienne Brain, Laurence Venat‐Bouvet, Alain Lortholary, Zbigniew Nowecki, Fátima Cardoso, Richard Hayward, Santiago Bella, Mauricio Fernández Lazzaro, N. Pilnik, Luis Fein, C. Blajman, Guillermo Lerzo, Mirta Varela, Juan José Zarbá, Diego Kaen, Maria Victoria Constanzo, Joke Tio, Wulf Siggelkow, Christian Jackisch, Eva Maria Grischke, D.-M. Zahm, Sara Tato-Varela, Sabine Schmatloch, Peter Klare, Andrea Stefek, Kerstin Rhiem, Oliver Hoffmann, Sherko Kümmel, Mustafa Deryal, Isolde Gröll, P. Ledwon, Christoph Uleer, Petra Krabisch, Jochem Potenberg, Maren Darsow, Tjoung‐Won Park‐Simon, Heinz‐Gert Höffkes, Till‐Oliver Emde, Gerd Graffunder, Oliver Tomé, Dirk Forstmeyer, Jürgen Terhaag, Christoph Salat, Karin Kast, Steffi Weniger, Carsten Schreiber, Bernhard Heinrich, Max Dieterich, Michaela Penelope Wüllner, Raquel Andrés Conejero, José Á. García-Sáenz, Lourdes Calvo, Angels Arcusa Lanza, Serafín Morales, Fernando Henao, Salvador Blanch Tormo, Isabel Álvarez, Juan Ignacio Delgado Mingorance, Elena Álvarez Gomez, Marta Santisteban, Josefina Cruz Jurado, Vanesa Quiroga, Manuel Ruiz Borrego, Eduardo Martínez de Dueñas, Jose Enrique Alés Martínez, Juan de la Haba-Rodríguez, Noelia Martínez-Jáñez, Álvaro Rodríguez Lescure, Antonio Antón, Gema Llort Crusades, Santiago González-Santiago, Antonia Marquez Aragones, A.L. Ortega Granados, A. Barnadas Molins, José Ignacio Chacón, M. Martín Jiménez, Ana Santaballa Bertrán, C. Rodríguez Rodríguez, Lucía González Cortijo, Elisabetta Cretella, Laura Cortesi, Enzo Maria Ruggeri, Claudio Verusio, Stefania Gori, Andrea Bonetti, Anna Maria Mosconi, Oskar T. Johannsson, Guy Jérusalem, Patrick Neven, Tünde Nagy, Graziella Pinotti, Marco Colleoni, Antônio Bernardo, Luca Gianni, Eugênio Bucci, Laura Biganzoli, Konstantin J. Dedes, Urban Novak, Khalil Zaman, Jeremy Braybrooke, Matthew Winter, Daniel Rea, Muireann Kelleher, Sophie Barrett, Stephen L. Chan, Tamas Hickish, Jane Hurwitz, John Conibear, A. Jegannathen, Marina Parton, Andrew Tutt, R. Allerton, Annabel Borley, Anne Armstrong, Ellen Copson, N C Levitt, Jean Abraham, Timothy Perren, Rebecca Roylance, Kazushige Ishida, Tatsuya Toyama, Norikazu Masuda, Junichiro Watanabe, Eriko Tokunaga, Takayuki Kinoshita, Yoshiaki Rai, Masahiro Takada, Yasuhiro Yanagita, Rikiya Nakamura, Takahiro Nakayama, Yasuto Naoi, Hiroji Iwata, Seigo Nakamura, Masato Takahashi, Kenjiro Aogi, Koichiro Tsugawa, Hirofumi Mukai, Toshimi Takano, Akihiko Osaki, Nobuaki Sato, Hideko Yamauchi, Yutaka Tokuda,
The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free ...
Elsevier BV
Shaimaa B. Al-Baghdadi, Ahmed A. Al‐Amiery, Tayser Sumer Gaaz, Abdul Amir H. Kadhum,
Abstract Most organic corrosion inhibitors have polar groups through which the molecule can be adsorbed strongly or specifically on the metal surface. In this investigation, terephthalo- hydrazide and isophthalohydrazide were synthesized as corrosion inhibitors, and their corrosion-inhibiting properties on mild steel were evaluated in a corrosive environment by weight loss measurements. The results of corrosion experiments revealed that terephthalohydrazide and isophthalohydrazide as inhibitors ...
Tópico(s): Hydrogen embrittlement and corrosion behaviors in metals
2021 - De Gruyter Open | Koroze a ochrana materialu
Mitchell R. Smith, Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir Parekh, David T. Yang, Lale Kostakoglu, Carla Casulo, Nancy L. Bartlett, Paolo F. Caimi, Tareq Al Baghdadi, Kami J. Maddocks, Mark D. Romer, David J. Inwards, Rachel E. Lerner, Lynne I. Wagner, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl,
7503 Background: Optimal initial therapy for mantle cell lymphoma (MCL) remains uncertain. The randomized phase 2 NCTN trial E1411 tested if progression-free survival (PFS) is prolonged by addition of bortezomib (V) (1.6 mg/m2 SC/IV days 1, 8) to bendamustine-rituximab (BVR vs BR) induction and/or by addition of lenalidomide (L) to rituximab (LR vs R) consolidation. Here we report efficacy and toxicity of induction BVR vs BR. Methods: 373 pts, accrued 2012–16, stratified by MIPI and age (≥60) received 1 ...
Tópico(s): Protein Degradation and Inhibitors
2021 - Lippincott Williams & Wilkins | Journal of Clinical Oncology